- Home
- JTAI vs NLSP Comparison
JTAI vs NLSP Comparison
Compare JTAI & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- NLSP
- Stock Information
- Founded
- JTAI 2018
- NLSP 2015
- Country
- JTAI United States
- NLSP Switzerland
- Employees
- JTAI N/A
- NLSP N/A
- Industry
- JTAI Blank Checks
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- JTAI Finance
- NLSP Health Care
- Exchange
- JTAI Nasdaq
- NLSP Nasdaq
- Market Cap
- JTAI 2.7M
- NLSP 243.8M
- IPO Year
- JTAI N/A
- NLSP 2021
- Fundamental
- Price
- JTAI $0.10
- NLSP $4.96
- Analyst Decision
- JTAI
- NLSP
- Analyst Count
- JTAI 0
- NLSP 0
- Target Price
- JTAI N/A
- NLSP N/A
- AVG Volume (30 Days)
- JTAI 97.0M
- NLSP 34.6K
- Earning Date
- JTAI 11-19-2024
- NLSP 11-01-2024
- Dividend Yield
- JTAI N/A
- NLSP N/A
- EPS Growth
- JTAI N/A
- NLSP N/A
- EPS
- JTAI N/A
- NLSP N/A
- Revenue
- JTAI $14,478,722.00
- NLSP N/A
- Revenue This Year
- JTAI $42.02
- NLSP N/A
- Revenue Next Year
- JTAI N/A
- NLSP N/A
- P/E Ratio
- JTAI N/A
- NLSP N/A
- Revenue Growth
- JTAI N/A
- NLSP N/A
- 52 Week Low
- JTAI $0.08
- NLSP $4.08
- 52 Week High
- JTAI $4.47
- NLSP $29.68
- Technical
- Relative Strength Index (RSI)
- JTAI 45.81
- NLSP 46.37
- Support Level
- JTAI $0.09
- NLSP $4.52
- Resistance Level
- JTAI $0.15
- NLSP $5.64
- Average True Range (ATR)
- JTAI 0.03
- NLSP 0.48
- MACD
- JTAI 0.00
- NLSP 0.07
- Stochastic Oscillator
- JTAI 12.77
- NLSP 55.44
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.